Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ultragenyx Pharmaceutical Inc    RARE

ULTRAGENYX PHARMACEUTICAL INC (RARE)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 12/14 10:00:04 pm
46.01 USD   -2.75%
2014Amid Alibaba fever, reasons for caution in IPO market
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 201520162017201820192020
Sales-0,132,6149,7102199
EBITDA-146-245-323-362-331-278
Operating profit (EBIT)-148-248-329-376-357-286
Pre-Tax Profit (EBT)-146-246-318-202-355-276
Net income-146-246-302-202-356-276
P/E ratio-28,3-11,3-6,51-11,5-6,97-9,30
EPS ( $ )-3,96-6,21-7,12-4,00-6,60-4,95
Dividend per Share ( $ )------
Yield------
Reference price ( $ )112.1870.3146.3846.0146.0146.01
Announcement Date02/25/2016
09:05pm
02/16/2017
09:05pm
02/20/2018
09:46pm
---
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 201520162017201820192020
Debt------
Finance437498244285252297
Operating income (EBITDA)-146-245-323-362-331-278
Leverage
(Debt/EBITDA)
------
Capital Expenditure4,9610,22,797,3014,739,0
Book Value Per Share (BVPS)13,7 $11,8 $8,68 $11,1 $8,06 $7,56 $
Cash Flow per Share-2,88 $-4,07 $-5,98 $-3,26 $-4,04 $-2,76 $
Announcement Date02/25/2016
09:05pm
02/16/2017
09:05pm
02/20/2018
09:46pm
---
Balance Sheet Analysis
Assessed data source :
© 2018 Thomson Reuters
Financial Ratios

Size 2018e 2019e
Capitalization 2 327 M$ -
Entreprise Value (EV) 2 042 M$ 2 076 M$
Valuation 2018e 2019e
P/E ratio (Price / EPS)
Capitalization / Revenue 46,8x 22,8x
EV / Revenue 41,1x 20,4x
EV / EBITDA -5,64x -6,28x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 4,15x 5,71x
Profitability 2018e 2019e
Operating Margin (EBIT / Sales) -756% -350%
operating Leverage (Delta EBIT / Delta Sales) - 0,05x
Net Margin (Net Profit / Revenue) -407% -349%
ROA (Net Profit / Asset) -47,6% -48,7%
ROE (Net Profit / Equities) -41,3% -64,2%
Rate of Dividend - -
Balance Sheet Analysis 2018e 2019e
CAPEX / CA   14,7% 14,5%
Cash Flow / Sales -332% -201%
Capital Intensity (Assets / Sales) 8,56x 7,17x
Financial Leverage (Net Debt / EBITDA) 0,79x 0,76x
EPS & Dividend